File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study

TitleUnderstanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study
Authors
KeywordsBarriers
Oral anticoagulants
Aspirin
Atrial fibrillation
Issue Date2020
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmchealthservres/
Citation
BMC Health Services Research, 2020, v. 20, article no. 1084 How to Cite?
AbstractBackground: Despite international treatment guidelines currently advocating oral anticoagulants (OACs) as the only appropriate stroke prevention therapy for patients with atrial fibrillation (AF) and evidence that OACs can greatly reduce the risk of stroke with similar risk of bleeding compared with aspirin, the underuse of OACs in patients with AF is common globally, especially in Asia. This study aimed to identify the barriers to prescribing and using OACs among long-term aspirin users with AF. Method: Face-to-face interviews were conducted with fourteen eligible patients with AF using a semi-structured interview guide. The interview recordings were transcribed verbatim and data was analyzed according to the principles of thematic analysis. Results: Five themes were developed: awareness of AF symptoms and diagnosis; knowledge and understanding of AF and stroke prevention therapy; role of decision-making in prescribing; willingness to switch from aspirin to OACs; and impact of OAC regimen on daily living. The majority of the patients were not aware of the symptoms and diagnosis of AF and only had a vague understanding of the illness and stroke prevention therapy, leading to their minimal involvement in decisions relating to their treatment. Some patients and their caregivers were particularly concerned about the bleeding complications from OACs and perceived aspirin to be a suitable alternative as they find the adverse effects from aspirin manageable and so preferred to remain on aspirin if switching to OACs was not compulsory. Lastly, the lifestyle modifications required when using warfarin, e.g. alternative dosing regimen, diet restriction, were seen as barriers to some patients and caregivers. Conclusion: The findings revealed patients’ knowledge gap in AF management which may be targeted using educational interventions to improve patients’ understanding of AF and its management and hence encourage active participation in the decision-making of their treatment in the future.
Persistent Identifierhttp://hdl.handle.net/10722/307892
ISSN
2021 Impact Factor: 2.908
2020 SCImago Journal Rankings: 1.098
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNg, VWS-
dc.contributor.authorSiu, CW-
dc.contributor.authorChiu, PKC-
dc.contributor.authorKng, CPL-
dc.contributor.authorJamieson, E-
dc.contributor.authorWong, ICK-
dc.contributor.authorLam, MPS-
dc.date.accessioned2021-11-12T13:39:25Z-
dc.date.available2021-11-12T13:39:25Z-
dc.date.issued2020-
dc.identifier.citationBMC Health Services Research, 2020, v. 20, article no. 1084-
dc.identifier.issn1472-6963-
dc.identifier.urihttp://hdl.handle.net/10722/307892-
dc.description.abstractBackground: Despite international treatment guidelines currently advocating oral anticoagulants (OACs) as the only appropriate stroke prevention therapy for patients with atrial fibrillation (AF) and evidence that OACs can greatly reduce the risk of stroke with similar risk of bleeding compared with aspirin, the underuse of OACs in patients with AF is common globally, especially in Asia. This study aimed to identify the barriers to prescribing and using OACs among long-term aspirin users with AF. Method: Face-to-face interviews were conducted with fourteen eligible patients with AF using a semi-structured interview guide. The interview recordings were transcribed verbatim and data was analyzed according to the principles of thematic analysis. Results: Five themes were developed: awareness of AF symptoms and diagnosis; knowledge and understanding of AF and stroke prevention therapy; role of decision-making in prescribing; willingness to switch from aspirin to OACs; and impact of OAC regimen on daily living. The majority of the patients were not aware of the symptoms and diagnosis of AF and only had a vague understanding of the illness and stroke prevention therapy, leading to their minimal involvement in decisions relating to their treatment. Some patients and their caregivers were particularly concerned about the bleeding complications from OACs and perceived aspirin to be a suitable alternative as they find the adverse effects from aspirin manageable and so preferred to remain on aspirin if switching to OACs was not compulsory. Lastly, the lifestyle modifications required when using warfarin, e.g. alternative dosing regimen, diet restriction, were seen as barriers to some patients and caregivers. Conclusion: The findings revealed patients’ knowledge gap in AF management which may be targeted using educational interventions to improve patients’ understanding of AF and its management and hence encourage active participation in the decision-making of their treatment in the future.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmchealthservres/-
dc.relation.ispartofBMC Health Services Research-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBarriers-
dc.subjectOral anticoagulants-
dc.subjectAspirin-
dc.subjectAtrial fibrillation-
dc.titleUnderstanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study-
dc.typeArticle-
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hk-
dc.identifier.emailChiu, PKC: chiukc@hku.hk-
dc.identifier.emailKng, CPL: cplkng@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authoritySiu, CW=rp00534-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12913-020-05947-3-
dc.identifier.pmid33238989-
dc.identifier.pmcidPMC7691100-
dc.identifier.scopuseid_2-s2.0-85096521244-
dc.identifier.hkuros329779-
dc.identifier.volume20-
dc.identifier.spagearticle no. 1084-
dc.identifier.epagearticle no. 1084-
dc.identifier.isiWOS:000595794700009-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats